{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:46:20Z","timestamp":1792784780425,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Bereits in den 1990er-Jahren zeigte Vogelstein, dass die Onkogenese h\u00e4ufig durch eine initiale \u201eTreibermutation\u201c ausgel\u00f6st wird, gefolgt von der Akkumulation weiterer genetischer Alterationen im Verlauf der Tumorprogression. Sowohl beim N\u00e4vus als auch beim Melanom ist\n                    <jats:italic>BRAF-V600E<\/jats:italic>\n                    oft diese Treibermutation, w\u00e4hrend zus\u00e4tzliche \u201esecond hits\u201c das Progressionsrisiko zum Melanom bestimmen.\n                  <\/jats:p>\n                  <jats:p>\n                    Die 5.\u00a0Auflage der WHO-Klassifikation der Hauttumoren f\u00fchrt den Begriff der Melanozytome (MZ) ein. Zu den in diesem Beitrag behandelten MZ z\u00e4hlen WNT-aktivierte, tief penetrierende\/plexiforme Melanozytome (DPN), pigmentierte epitheloide Melanozytome (PEM), BAP1-inaktivierte Melanozytome (BIM) sowie MITF-Signalweg-aktivierte melanozyt\u00e4re Tumoren. Allen MZ gemeinsam ist eine intermedi\u00e4re Biologie zwischen benignen N\u00e4vi und Melanomen mit geringem Progressionsrisiko, eine charakteristische Histopathologie sowie ein definierter molekularer Hintergrund. Dieser umfasst h\u00e4ufig eine\n                    <jats:italic>BRAF-V600E<\/jats:italic>\n                    - oder\n                    <jats:italic>MAP2K1<\/jats:italic>\n                    -Mutation sowie einen \u201esecond hit\u201c mit Aktivierung eines weiteren Signalwegs.\n                  <\/jats:p>\n                  <jats:p>\n                    MZ werden der Gruppe\u00a02 der Risikostratifizierung melanozyt\u00e4rer Neoplasien zugeordnet und sollten vollst\u00e4ndig exzidiert werden. Die Abgrenzung zum Melanom kann teilweise schwierig sein. In solchen F\u00e4llen kann ein Sicherheitsabstand von bis zu 1\u202fcm empfohlen werden. Bei Borderlinel\u00e4sionen hinsichtlich der Dignit\u00e4t sind molekulare Zusatzuntersuchungen, z.\u202fB. mittels Next-Generation Sequencing, oft hilfreich. Hinweisend auf ein Melanom sind die homozygote\n                    <jats:italic>p16<\/jats:italic>\n                    -Deletion, die\n                    <jats:italic>TERT<\/jats:italic>\n                    -Promotormutation oder mehr als 6\u00a0chromosomale Kopienzahlver\u00e4nderungen.\n                  <\/jats:p>","DOI":"10.1007\/s00292-026-01601-7","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:49:20Z","timestamp":1792086560000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Melanozytome","Melanocytomas"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-9958","authenticated-orcid":false,"given":"Daniela","family":"Mihic-Probst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1601_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50613","volume":"6","author":"RL Barnhill","year":"2023","unstructured":"Barnhill\u00a0RL, Elder\u00a0DE, Piepkorn\u00a0MW et\u00a0al (2023) Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A\u00a0Consensus Statement. JAMA Netw Open 6:e2250613","journal-title":"JAMA Netw Open"},{"key":"1601_CR2","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1530\/EJE-20-1120","volume":"184","author":"L Bouys","year":"2021","unstructured":"Bouys\u00a0L, Bertherat\u00a0J (2021) MANAGEMENT OF ENDOCRINE DISEASE: Carney complex: clinical and genetic update 20\u00a0years after the identification of the CNC1 (PRKAR1A) gene. Eur J Endocrinol 184:R99\u2013R109","journal-title":"Eur J Endocrinol"},{"key":"1601_CR3","doi-asserted-by":"crossref","unstructured":"Braat J, Trichy NS, Holic LJ et al (2026) The Impact of Next Generation Sequencing Studies on the Diagnosis of BAP1 Inactivated Melanocytic Tumors. Hum Pathol:106103","DOI":"10.1016\/j.humpath.2026.106103"},{"key":"1601_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100707","volume":"38","author":"L Chen","year":"2025","unstructured":"Chen\u00a0L, Chen\u00a0A, Sharma\u00a0N et\u00a0al (2025) Clinical, Morphologic, and Genomic Differences in Deep-Penetrating Nevi and Deep-Penetrating Nevus-like Melanomas. Mod Pathol 38:100707","journal-title":"Mod Pathol"},{"key":"1601_CR5","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P","volume":"70","author":"KR Cho","year":"1992","unstructured":"Cho\u00a0KR, Vogelstein\u00a0B (1992) Genetic alterations in the adenoma-carcinoma sequence. Cancer 70:1727\u20131731","journal-title":"Cancer"},{"key":"1601_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/PAS.0000000000000902","volume":"41","author":"JN Cohen","year":"2017","unstructured":"Cohen\u00a0JN, Joseph\u00a0NM, North\u00a0JP et\u00a0al (2017) Genomic Analysis of Pigmented Epithelioid Melanocytomas Reveals Recurrent Alterations in PRKAR1A, and PRKCA Genes. Am J Surg Pathol 41:1333\u20131346","journal-title":"Am J Surg Pathol"},{"key":"1601_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00837","volume":"10","author":"I Cosgarea","year":"2020","unstructured":"Cosgarea\u00a0I, Griewank\u00a0KG, Ungureanu\u00a0L et\u00a0al (2020) Deep Penetrating Nevus and Borderline-Deep Penetrating Nevus: A Literature Review. Front Oncol 10:837","journal-title":"Front Oncol"},{"key":"1601_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies\u00a0H, Bignell\u00a0GR, Cox\u00a0C et\u00a0al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954","journal-title":"Nature"},{"key":"1601_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/PAS.0000000000001630","volume":"45","author":"A De La Fouchardiere","year":"2021","unstructured":"De La Fouchardiere\u00a0A, Pissaloux\u00a0D, Tirode\u00a0F et\u00a0al (2021) Clear Cell Tumor With Melanocytic Differentiation and ACTIN-MITF Translocation: Report of 7 Cases of a Novel Entity. Am J Surg Pathol 45:962\u2013968","journal-title":"Am J Surg Pathol"},{"key":"1601_CR10","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1097\/PAS.0000000000001888","volume":"46","author":"A De La Fouchardiere","year":"2022","unstructured":"De La Fouchardiere\u00a0A, Tirode\u00a0F, Castillo\u00a0C et\u00a0al (2022) Attempting to Solve the Pigmented Epithelioid Melanocytoma (PEM) Conundrum: PRKAR1A Inactivation Can Occur in Different Genetic Backgrounds (Common, Blue, and Spitz Subgroups) With Variation in Their Clinicopathologic Characteristics. Am J Surg Pathol 46:1106\u20131115","journal-title":"Am J Surg Pathol"},{"key":"1601_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00428-020-03005-1","volume":"479","author":"A De La Fouchardiere","year":"2021","unstructured":"De La Fouchardiere\u00a0A, Blokx\u00a0W, van Kempen\u00a0LC et\u00a0al (2021) ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Arch 479:3\u201311","journal-title":"Virchows Arch"},{"key":"1601_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41379-021-00976-7","volume":"35","author":"M Donati","year":"2022","unstructured":"Donati\u00a0M, Martinek\u00a0P, Steiner\u00a0P et\u00a0al (2022) Novel insights into the BAP1-inactivated melanocytic tumor. Mod Pathol 35:664\u2013675","journal-title":"Mod Pathol"},{"key":"1601_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/his.15434","volume":"87","author":"JS Durgin","year":"2025","unstructured":"Durgin\u00a0JS, Zoumberos\u00a0NA, Novice\u00a0T et\u00a0al (2025) Role of single-nucleotide polymorphism microarray in the classification of BAP1-inactivated melanocytic tumours. Histopathology 87:110\u2013129","journal-title":"Histopathology"},{"key":"1601_CR14","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41379-022-01026-6","volume":"35","author":"CF Ebbelaar","year":"2022","unstructured":"Ebbelaar\u00a0CF, Schrader\u00a0AMR, Van Dijk\u00a0M et\u00a0al (2022) Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing. Mod Pathol 35:1110\u20131120","journal-title":"Mod Pathol"},{"key":"1601_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","volume":"144","author":"DE Elder","year":"2020","unstructured":"Elder\u00a0DE, Bastian\u00a0BC, Cree\u00a0IA et\u00a0al (2020) The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Arch Pathol Lab Med 144:500\u2013522","journal-title":"Arch Pathol Lab Med"},{"key":"1601_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/PAS.0000000000001195","volume":"43","author":"MC Isales","year":"2019","unstructured":"Isales\u00a0MC, Mohan\u00a0LS, Quan\u00a0VL et\u00a0al (2019) Distinct Genomic Patterns in Pigmented Epithelioid Melanocytoma: A Molecular and Histologic Analysis of 16 Cases. Am J Surg Pathol 43:480\u2013488","journal-title":"Am J Surg Pathol"},{"key":"1601_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/cup.70049","volume":"53","author":"JE Jeyakumar","year":"2026","unstructured":"Jeyakumar\u00a0JE, Addo\u00a0AK, Beydoun\u00a0HM et\u00a0al (2026) The Impact of Next-Generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Deep Penetrating Melanocytic Neoplasms. J\u00a0Cutan Pathol 53:293\u2013301","journal-title":"J Cutan Pathol"},{"key":"1601_CR18","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1097\/PAS.0b013e3181b94f3c","volume":"33","author":"RV Mandal","year":"2009","unstructured":"Mandal\u00a0RV, Murali\u00a0R, Lundquist\u00a0KF et\u00a0al (2009) Pigmented epithelioid melanocytoma: favorable outcome after 5\u2011year follow-up. Am J Surg Pathol 33:1778\u20131782","journal-title":"Am J Surg Pathol"},{"key":"1601_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock\u00a0PM, Harper\u00a0UL, Hansen\u00a0KS et\u00a0al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19\u201320","journal-title":"Nat Genet"},{"key":"1601_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1097\/PAS.0000000000001513","volume":"44","author":"SS Raghavan","year":"2020","unstructured":"Raghavan\u00a0SS, Saleem\u00a0A, Wang\u00a0JY et\u00a0al (2020) Diagnostic Utility of LEF1 Immunohistochemistry in Differentiating Deep Penetrating Nevi From Histologic Mimics. Am J Surg Pathol 44:1413\u20131418","journal-title":"Am J Surg Pathol"},{"key":"1601_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/pcmr.12412","volume":"28","author":"MR Roh","year":"2015","unstructured":"Roh\u00a0MR, Eliades\u00a0P, Gupta\u00a0S, Tsao\u00a0H (2015) Genetics of melanocytic nevi. Pigment Cell Melanoma Res 28:661\u2013672","journal-title":"Pigment Cell Melanoma Res"},{"key":"1601_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00000478-198901000-00005","volume":"13","author":"JA Seab Jr","year":"1989","unstructured":"Seab\u00a0JA Jr, Graham\u00a0JH, Helwig\u00a0EB (1989) Deep penetrating nevus. Am J Surg Pathol 13:39\u201344","journal-title":"Am J Surg Pathol"},{"key":"1601_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.survophthal.2005.12.011","volume":"51","author":"JA Shields","year":"2006","unstructured":"Shields\u00a0JA, Demirci\u00a0H, Mashayekhi\u00a0A et\u00a0al (2006) Melanocytoma of the optic disk: a review. Surv Ophthalmol 51:93\u2013104","journal-title":"Surv Ophthalmol"},{"key":"1601_CR24","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jaad.2014.07.026","volume":"71","author":"L Strazzula","year":"2014","unstructured":"Strazzula\u00a0L, Senna\u00a0MM, Yasuda\u00a0M, Belazarian\u00a0L (2014) The deep penetrating nevus. J\u00a0Am Acad Dermatol 71:1234\u20131240","journal-title":"J Am Acad Dermatol"},{"key":"1601_CR25","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jnci\/djy171","volume":"110","author":"S Walpole","year":"2018","unstructured":"Walpole\u00a0S, Pritchard\u00a0AL, Cebulla\u00a0CM et\u00a0al (2018) Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J\u00a0Natl Cancer Inst 110:1328\u20131341","journal-title":"J Natl Cancer Inst"},{"key":"1601_CR26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/PAS.0b013e3182498be5","volume":"36","author":"T Wiesner","year":"2012","unstructured":"Wiesner\u00a0T, Murali\u00a0R, Fried\u00a0I et\u00a0al (2012) A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 36:818\u2013830","journal-title":"Am J Surg Pathol"},{"key":"1601_CR27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/ng.910","volume":"43","author":"T Wiesner","year":"2011","unstructured":"Wiesner\u00a0T, Obenauf\u00a0AC, Murali\u00a0R et\u00a0al (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018\u20131021","journal-title":"Nat Genet"},{"key":"1601_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/DAD.0000000000003151","volume":"48","author":"BA Wood","year":"2026","unstructured":"Wood\u00a0BA, Shepard\u00a0S, James\u00a0C et\u00a0al (2026) BAP1-Inactivated Melanocytic Tumors With Distinctive p16-Negative Clonal Growth and Liver Metastases. Am J Dermatopathol 48:114\u2013117","journal-title":"Am J Dermatopathol"},{"key":"1601_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00758-3","volume":"8","author":"I Yeh","year":"2017","unstructured":"Yeh\u00a0I, Lang\u00a0UE, Durieux\u00a0E et\u00a0al (2017) Combined activation of MAP kinase pathway and beta-catenin signaling cause deep penetrating nevi. Nat Commun 8:644","journal-title":"Nat Commun"},{"key":"1601_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00000478-200401000-00002","volume":"28","author":"A Zembowicz","year":"2004","unstructured":"Zembowicz\u00a0A, Carney\u00a0JA, Mihm\u00a0MC (2004) Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol 28:31\u201340","journal-title":"Am J Surg Pathol"},{"key":"1601_CR31","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1097\/PAS.0b013e318057faa7","volume":"31","author":"A Zembowicz","year":"2007","unstructured":"Zembowicz\u00a0A, Knoepp\u00a0SM, Bei\u00a0T et\u00a0al (2007) Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions. Am J Surg Pathol 31:1764\u20131775","journal-title":"Am J Surg Pathol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01601-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01601-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01601-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:02:06Z","timestamp":1792782126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01601-7"}},"subtitle":["Intermedi\u00e4re melanozyt\u00e4re Neoplasien mit distinkter Morphologie und molekularem Hintergrund","Intermediate melanocytic neoplasms with distinct morphology and molecular background"],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s00292-026-01601-7","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"21 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.\u00a0Mihic-Probst und F.\u00a0Saro geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}